Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 04:00 ET | Source: Adrenomed AG

AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative

Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy...
April 10, 2024 08:00 ET | Source: Adrenomed AG

AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...
September 08, 2023 04:00 ET | Source: Adrenomed AG

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update

Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
February 21, 2020 08:20 ET | Source: Adrenomed AG

Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock

Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profileAdrecizumab demonstrates a positive trend on survivalAdrenOSS-2 is a biomarker-guided...